Oral Eplerenone for the Management of Acute Serous Chorioretinopathy

Zusatztext

To determine whether Eplerenone (Inspra,Pfizer), a mineralocorticoid receptor (MR) antagonist, is an effective treatment option for acute central serous chorioretinopathy (CSCR). A prospective analysis was conducted for patients who received off-label oral Eplerenone for the treatment of acute CSCR. Eplerenone was administered orally at a dose of 50mg daily, for a total of 28 days. Patients were observed at baseline and at 3 separate consult visits: 7; 14 and 28 days, with SD-OCT performed at each follow-up.The primary outcome measure of the study, was the best corrected visual acuity (BCVA) following Eplerenone administration. A prospective cohort of 15 eyes in 15 patients with acute CSCR were treated with 50mg/d Eplerenone for 28 days. After 28 days, statistically significant decreases from the baseline were observed in, SRF diameter (P<0.01), SRF height (P=0.001), CST (P<0.01), CV(P<0.01), and CAT (P=0.01). After 28 days, the BCVA was 0.9 +/- 0.1 (P=0.001), compared to baseline BCVA 0.8 +/- 0.1. Complete resolution of subretinal fluid (SRF) was seen in 8 out of 15 (53.3%) eyes. Eplerenone treatment accelerated SRF in acute CSCR, compared to the natural disease course.

Autorenportrait

Dr. Rebecca Grimes was born on the 20th May 1992 in Southport, GBR. She received her education at Merchant Taylors' Girls' School in the UK from 2003-2010 and went on to study Medicine at The University of Split in Croatia from 2011-2017. She is currently enrolled in her first year on a OBGYN specialist training scheme in the Republic of Ireland.

Weitere Details